Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Biosimilars Mvasi and Kanjinti are now available in the United States.
Cytoreductive nephrectomy (CN) by itself for metastatic renal cell carcinoma is associated with a 43% decreased risk of death compared with CN plus targeted therapy.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Prospective validation shows decrease in predictive ability compared with previous retrospective validations.
Access a treatment regimen chart with detailed information for renal cell carcinoma, including tyrosine kinase inhibitors and cytokine therapy.
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
The Food and Drug Administration has approved Bavencio (avelumab; EMD Serono), a programmed death-ligand 1 (PD-L1) blocking antibody, in combination with Inlyta (axitinib; Pfizer), a kinase inhibitor, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
